Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate.
Wien Med Wochenschr
; 172(15-16): 373-378, 2022 Nov.
Article
em En
| MEDLINE
| ID: mdl-35142953
ABSTRACT
BACKGROUND:
Natalizumab is an approved treatment for relapsing remitting multiple sclerosis; however, its safety during pregnancy is not formally proven. CASE PRESENTATION We report a woman with multiple sclerosis being treated with natalizumab before pregnancy. After withdrawal of natalizumab, she suffered a severe, disabling rebound. In agreement with the patient, natalizumab was restarted during pregnancy. Our patient improved substantially and gave birth to a healthy boy.CONCLUSION:
Use of natalizumab during pregnancy may be an option in highly active multiple sclerosis.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Esclerose Múltipla Recidivante-Remitente
/
Esclerose Múltipla
Tipo de estudo:
Prognostic_studies
Aspecto:
Ethics
Limite:
Female
/
Humans
/
Male
/
Pregnancy
Idioma:
En
Revista:
Wien Med Wochenschr
Assunto da revista:
MEDICINA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Áustria